These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 36598826)

  • 21. Potent and specific inhibition of the biological activity of the type-II transmembrane serine protease matriptase by the cyclic microprotein MCoTI-II.
    Gray K; Elghadban S; Thongyoo P; Owen KA; Szabo R; Bugge TH; Tate EW; Leatherbarrow RJ; Ellis V
    Thromb Haemost; 2014 Aug; 112(2):402-11. PubMed ID: 24696092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen receptor non-nuclear regulation of prostate cancer cell invasion mediated by Src and matriptase.
    Zarif JC; Lamb LE; Schulz VV; Nollet EA; Miranti CK
    Oncotarget; 2015 Mar; 6(9):6862-76. PubMed ID: 25730905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of kallikrein-related peptidases in prostate cancer: potential involvement in an epithelial to mesenchymal transition.
    Whitbread AK; Veveris-Lowe TL; Lawrence MG; Nicol DL; Clements JA
    Biol Chem; 2006 Jun; 387(6):707-14. PubMed ID: 16800731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kallikrein-related peptidase (KLK) family mRNA variants and protein isoforms in hormone-related cancers: do they have a function?
    Tan OL; Whitbread AK; Clements JA; Dong Y
    Biol Chem; 2006 Jun; 387(6):697-705. PubMed ID: 16800730
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.
    Danila DC; Anand A; Sung CC; Heller G; Leversha MA; Cao L; Lilja H; Molina A; Sawyers CL; Fleisher M; Scher HI
    Eur Urol; 2011 Nov; 60(5):897-904. PubMed ID: 21802835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kallikrein-related peptidase 4 (KLK4) initiates intracellular signaling via protease-activated receptors (PARs). KLK4 and PAR-2 are co-expressed during prostate cancer progression.
    Ramsay AJ; Dong Y; Hunt ML; Linn M; Samaratunga H; Clements JA; Hooper JD
    J Biol Chem; 2008 May; 283(18):12293-304. PubMed ID: 18308730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KLK-targeted Therapies for Prostate Cancer.
    Hannu K; Johanna M; Ulf-Håkan S
    EJIFCC; 2014 Sep; 25(2):207-18. PubMed ID: 27683469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kallikrein-Related Peptidases in Prostate Cancer: From Molecular Function to Clinical Application.
    Fuhrman-Luck RA; Loessner D; Clements JA
    EJIFCC; 2014 Oct; 25(3):269-81. PubMed ID: 27683474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nuclear receptor ERRα contributes to castration-resistant growth of prostate cancer via its regulation of intratumoral androgen biosynthesis.
    Xu Z; Ma T; Zhou J; Gao W; Li Y; Yu S; Wang Y; Chan FL
    Theranostics; 2020; 10(9):4201-4216. PubMed ID: 32226548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcriptome profiling and protease inhibition experiments identify proteases that activate H3N2 influenza A and influenza B viruses in murine airways.
    Harbig A; Mernberger M; Bittel L; Pleschka S; Schughart K; Steinmetzer T; Stiewe T; Nist A; Böttcher-Friebertshäuser E
    J Biol Chem; 2020 Aug; 295(33):11388-11407. PubMed ID: 32303635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer.
    Pampalakis G; Sotiropoulou G
    Biochim Biophys Acta; 2007 Sep; 1776(1):22-31. PubMed ID: 17629406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of protein kinase C-related kinase (PRK) signalling by the TPα and TPβ isoforms of the human thromboxane A
    O'Sullivan AG; Mulvaney EP; Kinsella BT
    Biochim Biophys Acta Mol Basis Dis; 2017 Apr; 1863(4):838-856. PubMed ID: 28108419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experimental evidence of persistent androgen-receptor-dependency in castration-resistant prostate cancer.
    Kobayashi T; Inoue T; Kamba T; Ogawa O
    Int J Mol Sci; 2013 Jul; 14(8):15615-35. PubMed ID: 23896594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aspirin Inhibits IKK-β-mediated Prostate Cancer Cell Invasion by Targeting Matrix Metalloproteinase-9 and Urokinase-Type Plasminogen Activator.
    Shi C; Zhang N; Feng Y; Cao J; Chen X; Liu B
    Cell Physiol Biochem; 2017; 41(4):1313-1324. PubMed ID: 28278500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
    McGowen R; Biliran H; Sager R; Sheng S
    Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kallikreins as biomarkers for prostate cancer.
    Hong SK
    Biomed Res Int; 2014; 2014():526341. PubMed ID: 24809052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nucleoporin 62 and Ca(2+)/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells.
    Karacosta LG; Kuroski LA; Hofmann WA; Azabdaftari G; Mastri M; Gocher AM; Dai S; Hoste AJ; Edelman AM
    Prostate; 2016 Feb; 76(3):294-306. PubMed ID: 26552607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The kallikrein-related peptidase family: Dysregulation and functions during cancer progression.
    Kryza T; Silva ML; Loessner D; Heuzé-Vourc'h N; Clements JA
    Biochimie; 2016 Mar; 122():283-99. PubMed ID: 26343558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.
    Avgeris M; Scorilas A
    Expert Opin Ther Targets; 2016 Jul; 20(7):801-18. PubMed ID: 26941073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Curcumin-targeting pericellular serine protease matriptase role in suppression of prostate cancer cell invasion, tumor growth, and metastasis.
    Cheng TS; Chen WC; Lin YY; Tsai CH; Liao CI; Shyu HY; Ko CJ; Tzeng SF; Huang CY; Yang PC; Hsiao PW; Lee MS
    Cancer Prev Res (Phila); 2013 May; 6(5):495-505. PubMed ID: 23466486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.